◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › BBIO › Net Income

BridgeBio Pharma Inc (BBIO) Net Income 2017–TTM

DATA UPDATED 2026-09-19

BridgeBio Pharma Inc annual net income for fiscal TTM was -$696 million, an increase of 4.5% from -$729 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

BBIO Annual Net Income

Net Income (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Net Income($696M)($729M)($536M)($643M)($481M)($563M)($449M)($260M)($131M)($31M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BBIO Quarterly Net Income

Net Income (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Net Income($152M)($164M)($197M)($183M)($182M)($167M)($265M)($162M)($73M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

More BBIO metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All BBIO financial statements → Interactive BBIO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.